Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Preclinical evidence of multiple mechanisms underlying trastuzumab resistance in gastric cancer

22 Feb 2016

Abstract excerpt

// Chiara Arienti 1 , Michele Zanoni 1 , Sara Pignatta 1 , Alberto Del Rio 2, 3 , Silvia Carloni 1 , Michela Tebaldi 1 , Gianluca Tedaldi 1 , Anna Tesei 1 1 Biosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy 2 Institute of Organic Synthesis and Photoreactivity (ISOF), National Research Council (CNR), Bologna, Italy 3 Innovamol Srls, Modena, Italy...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to HER2/EGFR in Cancer Research
Share to Monoclonal and Polyclonal Antibodies Research
Share to Peptidase Inhibition and Analysis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 26919099
DOI: 10.18632/oncotarget.7575

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Preclinical evidence of multiple mechanisms underlying trastuzumab resistance in gastric cancerPMID 26919099Read ↗

The genomics and therapeutics of HER2-positive gastric cancer—from trastuzumab and beyondSemantic proximity Read ↗

Exploring potential molecular resistance and clonal evolution in advanced HER2-positive gastric cancer under trastuzumab therapySemantic proximity Read ↗

Novel HER2-targeted therapy to overcome trastuzumab resistance in HER2-amplified gastric cancerSemantic proximity Read ↗

Genomic Profiling of HER2-Positive Gastric Cancer: PI3K/Akt/mTOR Pathway as Predictor of Outcomes in HER2-Positive Advanced Gastric Cancer Treated with TrastuzumabSemantic proximity Read ↗

Molecular Bases of Mechanisms Accounting for Drug Resistance in Gastric AdenocarcinomaSemantic proximity Read ↗

Prediction of key genes and pathways involved in trastuzumab-resistant gastric cancerSemantic proximity Read ↗

The root cause of drug resistance in HER2-positive breast cancer and the therapeutic approaches to overcoming the resistanceSemantic proximity Read ↗

A Comprehensive Outline of Trastuzumab Resistance Biomarkers in HER2 Overexpressing Breast CancerSemantic proximity Read ↗

Resistance to Anti-HER2 Therapies in Breast CancerSemantic proximity Read ↗

Development of trastuzumab-resistant human gastric carcinoma cell lines and mechanisms of drug resistanceSemantic proximity Read ↗

AKR1C mediates the acquired resistance to T-Dxd in a HER-2 positive gastric cancer lineSemantic proximity Read ↗

Deciphering the Role of Insulin-Like Growth Factor-I Receptor in Trastuzumab ResistanceSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.